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Abstract  
Motivation: Drug combination is a sensible strategy for disease treatment by improving the efficacy and reducing concomitant side effects. 
Due to the large number of possible combinations among candidate compounds, exhaustive screening is prohibitive. Currently, a plenty of 
studies have focused on predicting potential drug combinations. However, these methods are not entirely satisfactory in performance and 
scalability. 
Results: In this paper, we proposed a Network Embedding framework in Multiplex Networks (NEMN) to predict synthetic drug combinations. 
Based on a multiplex drug similarity network, we offered alternative methods to integrate useful information from different aspects and to 
decide quantitative importance of each network. To explain the feasibility of NEMN, we applied our framework to the data of drug-drug 
interactions, on which it showed better performance in terms of AUPR and ROC. For Drug combination prediction, we found seven novel drug 
combinations which have been validated by external sources among the top-ranked predictions of our model. 
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1 Introduction 
Drug combination therapies have been used for the treatment of complex 
disease such as cancer and Type II diabetes due to the advantage of higher 
efficacy, fewer side effects and less dose with less toxicity compared to single 
drug therapies(He, et al., 2016). The main reason is that complex disease 
is normally involved in multiple pathways and multiple genes, which limits the 
therapeutic opportunity of one-gene-one-drug. Despite the increasing number 
of drug combinations in use, many of them were found in clinic or by biological 
experience. The mechanistic understanding of synergistic drug combinations 
remains largely elusive, which makes it difficult to propose new drug 
combinations. Although many approaches have been proposed to seek drug 
combinations, there are always some inevitable limitations for them.  
To promote the development of in-silico methods for computing drug 
synergy, the Dialogue for Reverse Engineering Assessments and Methods 
(DREAM) consortium launched an international open challenge for the 
development of computational models that can be used to objectively and 
systematically evaluate the accuracy and specificity of drug synergy 
predictions. Experiments are needed for drugs with gene expression, but many 
drugs don’t have gene expression on all kinds of cell lines. Therefore high-
throughput screening seems to be the first choice. However, high-throughput 
screening method is not suitable to search drug combinations, because the 
large-scale experiments of possible drug combinations used are very 
consuming both in time and in money (Cokol, et al., 2011; Winter, et 
al., 2012) and it’s also not feasible to seek synergistic drug combinations.  
Some drug combination predictions using protein-protein networks are 
based on hypothesis that similar drugs can affect similar proteins (Jia, et al., 
2009). However, protein-protein network is biased in which some relations 
superficially exist while pharmacokinetic and pharmacodynamics are ignored. 
Of course, distance between drug targets in PPI network is an important 
 element in prediction of drug combinations. 
Molecular networks, such as signal transduction and gene regulatory 
networks are also used to predict drug combinations. Åsmund Flobak et al 
proposed logical model simulations which can be used to automate reasoning 
on network dynamics even with scarce knowledge of kinetic 
parameters(Flobak, et al., 2015), and have been used to describe and 
predict the behavior of molecular networks affected in human disease. However, 
molecular network is biased based on knowledge and simulated biological 
metabolism is not accurate. 
Alternatively, some computational approaches have been proposed, which 
use drug similar network weights as a features and train computational models 
to predict drug combinations(Atias and Sharan, 2011; Cheng and 
Zhao, 2014; Gottlieb, et al., 2012; Li, et al., 2015; Sridhar, 
et al., 2016; Vilar, et al., 2013). For example, Li et al proposed PEA 
to predict drug combinations using seven layer networks. But most of them 
often have limitations that the feature is fixed and involves only edges in 
similarity networks .Without consideration of nodes in the multiplex network, 
we can’t fully integrate topological information into the feature. 
Drug-drug interactions(DDIs) are classified as pharmacokinetic and 
pharmacodynamics. Pharmacokinetic interactions are usually associated with 
an adverse or exaggerated response and pharmacodynamics interactions are 
implicated in both synergistic and detrimental effects(Sridhar, et al., 
2016). Therefore, when the model got better performance in DDIs prediction，
it’s also suitable for drug combination prediction. 
Network embedding has achieved vast success in social network 
classification and clustering, such as DeepWalk, LINE and Grape. But these 
methods are only suitable for single-layer network, not applicable to multiplex 
networks data integration. OhmNet(a hierarchy-aware unsupervised node 
feature learning approach) need tissue hierarchy interactions. We consider 
different multiplex networks as sampling from real network in different aspects. 
But not every network has the same weight. 
In this paper, we proposed a framework called NEMN, which uses drug 
similar networks to predict synergistic drug combinations. Multiplex drug 
similarity network were built using drug multiple omics data. The novelty of 
NEMN can be seen in four aspects: (1) Complementary integration of the 
topology of multiplex networks into data feature. (2) Available to predict 
relations of drug-disease or drug-target. (3) Easy to scalable for more drug 
similar networks. (4) Use of different weights of importance when sampling 
multiplex networks. In consequence, our method got better results compared 
with INDI (Gottlieb, et al., 2012), PLS (Sridhar, et al., 2016) and 
mashup (Cho, et al., 2016) when using same drug similarity data from 
Gottlieb, et al. (2012) to predict drug-drug interactions. In the end, we 
predicted seven synergistic drug combinations and verified them by literature.  
2.Materials 
For Drug combination prediction, we calculated six similarity networks 
according to five drug-based as well as one target-based similarity measures, 
1284 drugs were preserved after we selected drugs existed in all six drug 
similarity networks. Drug combinations data were obtained from the Drug 
Combination Database (DCDB) (Liu, et al., 2010) and the website of food 
and drug administration (FDA). 
2.1 Drug-drug similarity network 
We defined and computed six drug-drug similarity measures, including the 
chemical similarity, the similarity based on side effect, the anatomical 
therapeutic and chemical (ATC) classification system similarity, the similarity 
based on text-mining, the similarity based on distances in a protein-protein 
interaction network, and firstly using the categories of drug similarity. 
2.1.1 Chemical similarity network 
We downloaded the data of small molecule drugs with detailed structural 
formula and molecule from DrugBank (Wishart, et al., 2018). Each 
vertex of the network was weighted by using molecular fingerprint feature 
vectors with 1024-dimensions by the calculation of the PaDEL-Descriptor 
software (Yap, 2011). In the binary vector, elements 1 or 0 indicate the 
presence or absence of a specific chemical substructure seperately. The 
molecular fingerprint feature has been widely used in the study of quantitative 
structure activity relationship (Dimova, et al., 2013; Rabal, et al., 
2015). A jaccard function was used to calculate drug similarity based on 
1024-dimensions mentioned above. 
2.1.2 ATC similarity network.  
The Anatomical Therapeutic Chemical (ATC) Classification System, which 
includes 5 different hierarchical levels, was used to classify drugs into different 
groups according to the organ they acted on and the therapeutic chemical 
characteristics. The similarity between two ATC codes is derived according to 
their prior probabilities (frequency) and the probability of their commonality 
(Zhao and Li, 2010), which is defined as their longest matched prefix: 
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where ( , )prefix i j is the longest matched prefix of ATC code i  and j . 
Note that drugs may have more than one ATC code, we then define the 
maximum ATC code similarity as TS: 
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where ( )ATC d  represents all the ATC codes belonging to drug d .  
 2.1.3 Side-effect similarity network 
Drug side effects were obtained from SIDER 4.1 (http://sideeffects.embl.de/) 
(Kuhn, et al., 2016), a public resource containing drug side-effect 
information. We assigned a side-effect profile to each drug in our dataset, 
whose elements encode for the presence or absence of each of the side-effect 
by using 1 or 0 respectively. As mentioned above, we defined and computed 
similarity scores between drugs according to jaccard similarity score between 
their side-effect profiles. 
2.1.4 Text-mining similarity network 
We downloaded drug-drug similarity score from stitch dataset 
(http://stitch.embl.de/) based on the times of their cooccurrence in the same 
paper (Szklarczyk, et al., 2015). 
2.1.5 Target distance similarity network 
The similarity between each pair of drug target proteins in the human PPI 
network was calculated by using the shortest distance between drug targets. PPI 
network was downloaded from human protein reference database (HURM) 
(Keshava Prasad, et al., 2009). We transformed distance to similarity 
by the formula as fellow. 
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The similar equals to 1 when distance equals to 0. The similar becomes 
smaller as the distance becomes larger. 
 
2.1.6 Category similarity network 
We firstly used the categories of drug to describe information about drugs. The 
categories of drug reflect the compound and pharmacology of drugs. We 
assigned a category profile to each drug from DrugBank, whose elements 
encode for the presence or absence of each of the categories using 1 or 0 
respectively. As mentioned above, we defined and computed similarity score 
between drugs according to jaccard similarity score between their category 
profiles. 
 
1284 drugs were preserved after we selected drugs exsited in all six drug 
similarity networks. As a result, six drug similarity networks were homologous 
and heterogeneous and each layer of network has exactly 1284 nodes. 
2.2 Drug combination data 
We downloaded drug combinations from DCDB dataset and the website of 
food and drug administration (FDA). 275 pairs of drug combination were 
obtained from FDA to evaluate the importance of different drug similarity 
networks. There remained to be 947 pairs of drug combination from DCDB 
after the removal of those that already existed in FDA. But after overlapping 
1284 drugs in similarity networks with those in chosen drug combinations, we 
finally obtained 239 and 275 pairs of drug combination respectively from  
DCDB and FDA as positive samples.  
3 Methods  
3.1 evaluate network importance 
We think drug similarity networks reflected drug similarity from different 
aspects, each of network had different information volume and absolutely 
should have different weights to represent network importance. So, we used a 
part of data, such as, drug combination or DDIs to evaluate the importance of 
each network. For each of network, we found that the edge weight between 
known drug combinations in networks was higher than that between randomly 
selected ones when using Wilcoxon rank-sum statistic to sample 1,000,000 
instances. So six drug similarity networks had information about drugs and 
each of them had different topological structure. The weight of synergistic drug 
combinations is larger than that of randomly sampled edges, which has been 
proved by Zhao, et al. (2011). It’s approved that the network in which the 
edge weights of known drug combinations have greater significance than in 
other networks has more and accurater information. We used p-values 
calculated by Wilcoxon rank-sum statistic to weight each network in the form 
of a decreasing function. The weight of the network is used as the times of 
sampling from the according network. 
According to the algorithm of DeepWalk (Perozzi, et al., 2014) 
and Node2Vec(Grover and Leskovec, 2016), the weights of the 
network usually set 10 and we also followed this chosen. We considered 10 as 
the mean of weights of networks and slightly modified the weight according 
the p-value calculated by Wilcoxon rank-sum statistic. It’s reasonable when the 
smaller p-value compared with the bigger weight, because the weight and p-
value is relative to other weight and p-value. According to the paper of Grover, 
et al(Grover and Leskovec, 2016)., weights should be about 10. After 
experiment, we think the weight is not sensitive to the result but should not be 
too big or too small. 
3.2 network information sampling 
We achieved this by utilizing a flexible biased random walk procedure that can 
explore neighborhoods to sample drug similarity networks. 
 3.2.1 Random Walks 
Formally, given a source node u , we simulate a random walk of fixed length L . 
Let iC  denote the i th node in the walk, starting with 0C u . Nodes iC  
are generated by the following distribution: 
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Where vxW  is the normalized transition probability between node v  and 
node x  (Grover and Leskovec, 2016). 
3.2.2 Biased random walk 
Random walk does not allow us to account for the network structure and guide 
our search procedure to explore different types of network neighborhoods. We 
used a 2nd order random walk with two parameters p  and q  refer to 
node2vec (Grover and Leskovec, 2016) with a piecewise functions 
which guide the walk as following : Consider a random walk that just traverses 
edge (t, v) and resides at node v. The walk now needs to decide on the next step 
so it evaluates the transition probabilities ,v xW on edges (v, x) leading from v. 
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We set the unnormalized transition probability to ( , )vx vxW t x W , 
where txd denotes the shortest path distance between nodes t and x . Note 
that txd  must be one of {0, 1, 2}, and hence the two parameters are necessary 
and sufficient to guide the walk. Finally, we used biased random walk to acquire 
many paths. 
3.3 FEATURE LEARNING 
Random walk sequences are considered as sentences in natural language 
processing in which a node equals to a word, so we used Word2Vec method 
provide by Google(Le and Mikolov, 2014). 
3.3.1 SkipGram 
SkipGram (Le and Mikolov, 2014; Mikolov, et al., 2013) is a 
language model that maximizes the cooccurrence probability among the words 
that appear within a window ( k ) in sequences. 
SkipGram tries to maximize classification of a node based on another 
node in the same path. More precisely, we use each current node as an input to 
a log-linear classifier with continuous projection layer and then predict nodes 
within a certain range before and after the current node in the biased random 
walk path. We found that increasing the range improves quality of the resulting 
node vectors, but it also increases the computational complexity. Since the 
more distant words are usually less related to the current node than those close 
to it, we give less weight to the distant node by sampling less from those nodes 
in our training examples. We need to sure the distance of window in the biased 
random walk path. Where we set k = 5(see appendix), all possible collocations 
in random walk that appear within the window k  were considered as positive 
sample and negative sample using negative sample (Mikolov, et al., 
2013) to generated. Given the representation of 
jV , we would like to 
maximize the probability of its neighbors in the walk. 
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[ - : ]P j w j w  representated nodes appear in random walk path has distance 
smaller than the window size of k . The function of Pr  is equal to logistic 
classifier. It’s also suitable for formula 6 and 7. 
3.3.2 Optimization 
The optimization phase is made efficient using asynchronous stochastic 
gradient (SGD) (Bottou, 1991). 
The training objective of the Skip-gram model is to find node 
representations that are useful for predicting the surrounding nodes in a random 
walk path. More formally, given a lots of random walk paths training nodes 1v ,
2v , 3v , . . . , Lv , the objective of the Skip-gram model is to maximize the average 
log probability  
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The basic Skip-gram formulation defines using the softmax function as fellow. 
'
'
1
exp( )
( | )
exp( )
O I
w I
T
v v
O I N
T
v v
w
d d
p v v
d d



                      (8) 
where vd  and 
'
vd  are the input and output vector representations of v  
and N is the number of nodes in the Nodes. 
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Fig 1.Workflow for NEMN. Multiplex homologous heterogeneous drug similarity networks were built on DrugBank, SIDER and STITCH database, and each 
network has N drug node. The result is N dimension importance vectors by using a part of drug combination data to evaluate the importance of each of drug similarity 
network. A biased random walk method was adopt to sampling network to obtain random walk paths, and every network got different number of paths. Drug node 
vectors and classifier were combined to predict drug combination. 
 4 Results 
NEMN got better performance compared with the baseline function of INDI 
and Probabilistic Soft Logic(PSL) model, mashup， and two variant of NEMN 
in DDIs predict task. After that, NEMN was tenstedin Drug Combination 
Predication and analysis the result of drug combination predicted. 
The paragraph should be reorganized. You can say: 
We first test the performance of NEMN in *** task, by comparing with ***. 
The results showed ***. Then we test NEMN in *** task, by comparing with 
***. The results showed ***. 
4.1 evaluate NEMN by using other data and in comparison with other 
methods 
We used drug-drug interactions and drug similarity from Gottlieb, et al. 
(2012), the dataset contains two types of interactions: (1) CYP-related 
interactions (CRDs), (2) non-CYP related interactions (NCRDs), including 
10,106 CRD and 45,737 NCRD DDIs across 807 drugs. Meanwhile, Seven 
drug similarity networks(chemical-based, Ligand-based, side-effect-based, 
annotation-based target-sequence-based, target-PPI network-based, target-
Gene Ontology-based ) are also provided by Gottlieb, et al. (2012) 
INDI was often used as the baseline for DDIs prediction, based on seven 
drug similarity network, and 49 features were constructed by INDI(). The 
Probabilistic Soft Logic(PSL) model was used for DDIs prediction and got 
better performance when compared with INDI using same data. Mashup is a 
feature learning algorithm that learns low-dimensional representations for 
nodes based on their steady-state topological positions in the networks. It’s 
similar to NEMN, also got nodes feature for prediction. 
Two variant of NEMN also was taken into account for committed to 
validate the novelty of the method of NEMN. We designed NB_NEMN which 
used random walk rather than biased random walk and NS_NEMN which gave 
same weights for each network rather than evaluate the importance of each 
network. 
. Firstly, we randomly selected 20% interactions from CRD interactions 
or NCRD interactions with edge weights equal to 1. After that, we evaluated 
network importance by Wilcoxon rank-sum statistic to compare the elaborately 
selected 20% interactions with randomly selected edges from the same 
similarity network. Tabel-1 showed weights and p-values by Wilcoxon rank-
sum test. It has been confirmed by DeepWalk and node2vec that the weights 
for each network should be about 10.  
We used biased random walks of length 80 to sample networks by using 
p=1 and q=3(equals to node2vec). The weights calculated above used to ensure 
the times of sampling from node in each similarity network. We got many paths 
including every drug similarity network information and network topology. 
Drug node vector was easy to get by using Word2vec model which can provide 
many biased random walk paths. We discussed the result of prediction using 
biased random walk and random walk later. 
 
Table 1.Weights of drug similarity network and p-value using Wilcoxon rank-
sum test in drug-drug interactions data. 
  CRD NCRD 
 p-value weights p-value weights 
ATC 1.7e-5 8 2.5e-275 12 
Chemical 6.8e-05 10 0 15 
Distance 2.2e-06 11 0 15 
GO 5.9e-2 5 0 15 
Ligand 2.8e-4 7 1.8e-66 8 
Seqs 7.6e-46 15 0 15 
Sise Effect 4.6-09 13 1.2e-57 8 
 
A random forest classifier was adopted to classify the CRD interactions 
and NCRD interactions. The selection of parameters in the model followed 
supplementary materials. NEMN, mashup, NS_NEMN and NB_NEMN used 
the same parameters in random forest classifier to predict interactions. We not 
directly considered splice two drug node vector as feature to classify, because 
two different features represent the same of drug combination wasn’t 
reasonable. So, we use Euclidean distance in every dimension of the feature. 
Finally, 50 dimension vector was used to represent drug combination. 10-fold 
cross-validation was used for the evaluation. We applied the six methods to 
each fold and reported average and standard deviations of our chosen metrics 
for each one. Tables 1–2 presented average and standard deviations for recall, 
AUPR and AUC in cross-validation experiments. 
 From Table 2(right ?), we can see NEMN significantly outperformed 
both baselines in AUC, AUPR and F1-score when experimenting on two types 
of interactions. For AUPR in the best case, NEMN improved up to 62% over 
the PSL in which it ranged from 0.34 to 0.91. Mashup also got high AUC, 
AUPR and recall, which indicated the method exploiting node embedding may 
be more effective in predication when using multiplex network data. And 
compared with mashup, NEMN also got better performance. 
 
Table 2. Average AUPR, AUC and F1 scores, and standard deviation for 10-
fold CV for CRD interactions 
Method AUPR  AUROC  F1  
INDI  0.15+/-0. 007 0.92+/-0.003  0.24 +/- 0.005 
PSL  0.34+/- 0.02  0.96+/-0.003  0.40 +/- 0.02 
NEMN  0.918+/-0.01 0.979+/-0.01  0.944 +/- 0.01 
Mashup  0.92+/-0.01 0.977+/-0.01 0.94 +/- 0.01 
NS_NEMN 0.918+/-0.01 0.977+/-0.01 0.942 +/- 0.01 
NB_NEMN 0.916+/-0.01 0.976 +/- 0.01 0.941 +/- 0.01 
 
Table 3. Average AUPR, AUC and F1 scores, and standard deviation for 10-
 fold CV for NCRD interactions 
Method AUPR AUROC F1 
INDI 0.64 +/- 0.01 0.95 +/- 0.003 0.63 +/- 0.01 
PSL 0.78 +/- 0.02 0.97 +/- 0.003 0.70 +/- 0.02 
NEMN 0.964+/-0.01 0.993+/-0.01 0.943+/-0.01 
mashup 0.962+/-0.01 0.993+/-0.01 0.938 +/-0.01 
NS_NEMN 0.962+/-0.01 0.992+/-0.01 0.943+/-0.01 
NB_NEMN 0.963+/-0.01 0.992+/-0.01 0.941+/-0.01 
 
On the whole, Feature learning methods more suitable for DDIs 
prediction when used multiplex network as input. Mashup and NEME 
significantly outperformed INDI and PSL in AUC, AUPR and F1-score in CRD 
and NCRD interactions. For AUPR in the best case in CRD interactions, the 
two models improved up to 62% and 83% over PSL and INDI respectively. For 
AUC, the two models had comparative accuracy with PSL. For F1-score, 
NEME improved nearly 20% over PSL. Interestingly, the three different kinds 
of NEME and mashup method always performed better than INDI and PSL. 
This finding demonstrated the effectiveness in combining multiple similarities 
of NEMN. As for Table2, the result is similar to Table1, NEMN outperformed 
PSL and INDI considering AUPR and F1-score. 
To assess the benefit of using biased random walk and the meaning of 
evaluating network importance, we also compared NEMN model with 
NS_NEMN and NB_NEMN. It is shown that biased random walk can lead to 
better results.  
 
4.2 Drug Combination 
Drug combinations were obtained from section 2.2, and drug similarities from 
section 2.1. After that, we got 514 pairs of drug combination among which 275 
were from FDA and 239 from DCDB. Drug similarity networks were 
homologous networks, each of which were built based on different similarity 
measures and contained the same 1287 nodes. 
Firstly, we evaluated network importance by using drug combinations 
from FDA. By mapping drug combinations from FDA to each drug similarity 
network, we got an edge list for each network. We compared edge weights of 
drug combinations with that of randomly selected edges from networks and got 
p-values by using Wilcoxon rank-sum statistic. We found that drug 
combinations has greater weights compared with randomly selected edges, 
which agreed with the conclusion by Zhao, et al(Zhao, et al., 2011). So 
we assigned the similarity network with higher weights when its according p-
value was smaller. Tabel-4 showed weights and p-values by Wilcoxon rank-
sum test in each drug similarity network. 
 
Table 4.Weights of drug similarity network and p-value using Wilcoxon 
rank-sum test in combination data. 
Network p-value weights 
ATC 2.90153447482e-29 15 
Indication 3.69223052984e-22 13 
Text-mining 9.87695010037e-36 18 
Side-effect 4.00275686413e-10 10 
chemical 0.0792944676514 5 
Drug-target distance 2.29044980103e-05 8 
 
Secondly, we used biased random walks of length 80 to sample networks 
by using p=1 and q=3(equals to node2vec). The weights calculated above used 
to sure the times of sampling from node in each similarity network. We got 
many paths including every drug similarity network information and network 
topology.  
Using Word2vec algorithm to calculated drug node vector. Mang 
parameters in word2vec, we selected same parameters with node2vec, and 
output size we set to 5, due to we had 416 pairs drug combination as positive. 
high dimension lead to overfitting. Other drug combination predict methods 
has many features and just has hundreds of drug combination pairs. Overfitting 
is a potentially problem in drug combination prediction due to little drug 
combination data especially in using multi-layer machine learning to drug 
combination prediction. 
 
Fig. 2: Receiver Operating Characteristic (ROC) and Precision-recall curves in 
Drug combination Prediction. 
 
We calculated ROC and AUPR by using different network data. To 
quantitatively assess the performances of the NEMN model with all six features 
or each single feature in predicting effective drug combinations, we used the 
416 drug combination pairs as positive of our gold standard and negative 
samples that random selected four times of the size of positive from all drug 
pairs. A 10-fold cross validation accompanied with the receiver operating 
characteristic (ROC) curve analysis. As a result, the model with whole features 
(AUC=0.95) exhibits better performance than those with single feature 
(AUC=0.81–0.94) (Fig. 2). Among the six features, textmining has the most 
predicting performance (AUC=0.94). For AUPR, six features was also got 
more performance of 0.86. It turns out that the whole-feature NEMN model 
performance better than single feature. 
To validate the reliability of our method, we further check whether the 
predicted drug pairs were validated in external literatures which were not used 
to build the training dataset for the NENG model. Due to negative samples are 
unknown, we every train model using different negative samples that random 
selected from all drug pairs. So, we trained three classifiers using same positive 
sample and different negative sample. The results we predicted drug 
 combinations meanwhile exist in three different classifiers predicted results and 
top-300 in every classifier. We chose random forest classifier to train model. 
The result of drug combination index sort by the sum of different classifier 
index. Finally, we think sort in top and not in positive sample are predicted by 
NEMN model. 
4.3 External literature validation 
To validate the reliability of our method, we further check whether the predicted 
drug pairs were validated in external literatures which were not used to build 
the training dataset for the NENG model. (See Table5). 
We rank these new predictions and consider the top 30 interactions and 
not contain in train data as shown in Table-5, it’s our prediction. So, we need 
to validate in literature. 
 
Table 5. Top ranked NEMN model predictions for interaction unknown in drug  
combination. 
 
The top predicted drug combination is between DB00515 and 
DB001229 corresponding to Cisplatin and Paclitaxel, both cisplatin/paclitaxel 
regimens showed excellent activity with manageable toxicity in patients with 
advanced ovarian cancer has proved by De Jongh F E et al with a randomised 
phase I/II trial in 49 patients with ovarian cancer. Another evidence is 
Gynecological Oncology Group trial comparing cisplatin and 
cyclophosphamide versus cisplatin and paclitaxel. The response rate for the 
cisplatin and paclitaxel combination was 77%, with a median survival that was 
13.1 months longer than that of the cisplatin and cyclophosphamide-treated 
group. Based on this trial, cisplatin and paclitaxel became the standard first-
line treatment regimen for patients with advanced ovarian cancer(de Jongh, 
et al., 2002). 
For the combination of DB00232 and DB00999 hasn’t been proved by 
any literature. But the target of DB00232 were Q13621, P00915, P00918 and 
P22748 has two same target of DB00999. In the paper of Zhao, et al. 
(2011) found among 281 such pairs of drugs has proved by FDA, 100 share 
target proteins - a significantly higher proportion than expected by chance.(p-
value of 10−5, Fisher's exact test) So, DB00232 and DB00999 maybe has 
synerstic effect. 
All of these drug combination pairs has proved by experiments in 
patients, and it’s the most reasonable way to explanated drug combination result 
was accuracy. 
5 Discussion 
Developing combinatorial therapies for complex disease treatment has 
attracted increasing attention due to their great potentials as compared to 
monotherapies. One major challenge to develop combinatorial therapies is the 
large search space of possible combinations, therefore computationally 
predicting drug combination effects and prioritizing drug combinations is 
vitally important. In this paper, we have proposed  a computational framework 
NEMN to predict drug combination pairs. 
In drug-drug interactions prediction, we observed that NEMN has better 
performance than pervious work like INDI and PSL, and method based on node 
embedding such as mashup also has high AUC and AUPR. By construct multi-
layer drug similarity network to description drug interaction. Previous drug 
combination work has fixed feature that similarity network edge weights, it’s 
can’t combine network topology information with drug similarity to feature. So, 
feature is limited, can’t using feature to description drug interaction accurately.  
A framework based on network embedding were proposed by ours to 
dell with multi-layer homologous heterogeneous node vector representation. 
Two novelty of NEMN are using biased random walk and evaluate network 
importance has proved in Drug-Drug interactions prediction task. We sample 
multi-layer networks using biased random walk and evaluate each of network 
has different weights got better performance. Due to NEMN is data driven, not 
based on any hypothesis, we can use NEMN method in all kinds of situation, 
only input are multi-layer network or single-layer network and need a bit of 
prediction interactions.  
For drug combination prediction, the top-30 ranker in NEMN method 
has been validate in literature, and all of them got well performance in biology 
experiment especially in Phase I or II in Clinical cancer patients. There are 
several directions worth explorations in future studies. First, We proposed 
framework not only drug-drug interactions prediction, but also for all 
interactions prediction. Such as Drug-Target interactions prediction, Drug-
Disease interactions prediction. Second, we compared single-layer network 
with multi-layer network results ,in which indicate multi-layer network better 
proformance than single-layer network. We just using six drug similarity 
networks, many others drug similarity network can be take including GO 
information and pathway information into account. Different aspects 
information for drug can accuracy description drug, NEMN method also can 
using a more reasonable vector to represent drug node. 
Of course, some parameters should be talk feature, Zeng at al proposed 
to prediction drug-target interaction when using 500 dimension vector to 
represent drug node and 100-dimension vector to represent target node when 
just using 100*2000 drug-target interaction(Luo, et al., 2017). Higher 
dimension usually reflect overfitting. A Fatal weakness of network embedding 
is that not evaluate the vector of node reasonability. Node vector as feature to 
ALL 
Rank 
DrugBank_ID DrugBank_ID Predict 
Rank 
Pubmed ID 
4 DB00515 DB01229 1 12376205 
7 DB00232 DB00999 2  
12 DB00790 DB00999 3 9048272 
22 DB00530 DB01101 4 23393373 
27 DB00530 DB01229 5 20332457 
30 DB00999 DB04861 6 20556921 
 classify interactions can’t give a reasonable biological explanation. It’s also the 
weakness of NEMN. 
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